EUVIMEDEUVIMED entdecken
Crossref

Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit

Matthieu Roulleaux Dugage, Camille Mazza, Paul Matte, Cyril Roussel-Simonin, Arnaud Bayle, Antoine Hollebecque, Kaïssa Ouali, Madona Sakkal, Anas Gazzah, Jean-Marie Michot, Rastislav Bahleda, Thomas Hueso und 12 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.117058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Matthieu Roulleaux Dugage und 23 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Drug Development Department (DITEP), INSERM (U1363, U981), Paris Saclay University, Villejuif, France. Electronic address: matthieu.r…. Hauptthemen laut MEDLINE: Neoplasms, Clinical Trials, Phase I as Topic, Referral and Consultation, Antineoplastic Agents. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Fondation ARC pour la Recherche sur le Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsClinical Trials, Phase I as TopicReferral and ConsultationAntineoplastic AgentsHealth Services AccessibilityHumansRetrospective StudiesFemaleMaleMiddle AgedFranceAgedAdultTreatment Outcome

Stichwörter der Autor:innen

Access to clinical trialsDrug developmentPhase I clinical trials

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Gustave Roussy, Drug Development Department (DITEP), INSERM (U1363, U981), Paris Saclay University, Villejuif, France. Electronic address: matthieu.roulleaux-dugage@gustaveroussy.fr.
  • Institut Godinot, Early Phase Trial Unit, Reims, France.
  • Gustave Roussy, Drug Development Department (DITEP), Medical Oncology Department, Villejuif, France.
  • Gustave Roussy, Drug Development Department (DITEP), Medical Oncolo Deparment, Interdisciplinary Department of Patient Pathway Coordination (DIOPP), Villejuif, France.
  • Gustave Roussy, Drug Development Department (DITEP), Hematology Department, Villejuif, France.
  • Gustave Roussy, Drug Development Department (DITEP), INSERM (DNA repair, chromatin remodeling and epigenetics U981), Villejuif, France.

Förderung

  • Fondation ARC pour la Recherche sur le Cancer

Zitieren

APA

Roulleaux Dugage, M., Mazza, C., Matte, P., Roussel-Simonin, C., Bayle, A., Hollebecque, A., Ouali, K., Sakkal, M., Gazzah, A., Michot, J. M., Bahleda, R., Hueso, T., Patrikidou, A., Postel-Vinay, S., Pobel, C., Danlos, F. X., Ribrag, V., Baldini, C., Borget, I., …, & Massard, C. (2026). Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.117058

Vancouver

Roulleaux Dugage M, Mazza C, Matte P, Roussel-Simonin C, Bayle A, Hollebecque A, et al. Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.117058

BibTeX
@article{RoulleauxDugage2026,
  author = {Roulleaux Dugage, Matthieu and Mazza, Camille and Matte, Paul and Roussel-Simonin, Cyril and Bayle, Arnaud and Hollebecque, Antoine and Ouali, Kaïssa and Sakkal, Madona and Gazzah, Anas and Michot, Jean-Marie and Bahleda, Rastislav and Hueso, Thomas and Patrikidou, Anna and Postel-Vinay, Sophie and Pobel, Cédric and Danlos, François-Xavier and Ribrag, Vincent and Baldini, Capucine and Borget, Isabelle and André, Fabrice and Barlesi, Fabrice and Loriot, Yohann and Marabelle, Aurélien and Massard, Christophe},
  title = {Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.117058}
}
Kostenlos starten →